Persistent monocytosis after intravenous immunoglobulin therapy correlated with the development of coronary artery lesions in patients with Kawasaki disease

Journal of Microbiology, Immunology and Infection

Volumn 40, Issue 5, 2007, Pages 395-400

  Kuo, Ho Chang ^a   Wang, Chih Lu ^b   Liang, Chi Di ^c   Yu, Hong Ren ^a   Chen, Hsin Hsu ^a   Wang, Lin ^a   Yang, Kuender D ^a,c  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b Po Jen Hospital   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

C reactive protein; Coronary arteriosclerosis; Mucocutaneous lymph node syndrome

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; IMMUNOGLOBULIN;

ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD CELL COUNT; CLINICAL FEATURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; HUMAN; LEUKOCYTE DIFFERENTIAL COUNT; MAJOR CLINICAL STUDY; MALE; MONOCYTOSIS; MUCOCUTANEOUS LYMPH NODE SYNDROME; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK FACTOR; SINGLE DRUG DOSE; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

C-REACTIVE PROTEIN; CHILD, PRESCHOOL; CORONARY VESSELS; ECHOCARDIOGRAPHY; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFANT; LEUKOCYTOSIS; MALE; MONOCYTES; MUCOCUTANEOUS LYMPH NODE SYNDROME; RETROSPECTIVE STUDIES; STATISTICS AS TOPIC;

EID: 38049067665     PISSN: 16841182     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Kawasaki T, Kosaki F, Okawa S, Shigematsu I, Yanagawa H. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics. 1974;54:271-6.
2. Holman RC, Curns AT, Belay ED, Steiner CA, Effler PV, Yorita KL, et al. Kawasaki syndrome in Hawaii. Pediatr Infect Dis J. 2005;24:429-33.
3. Yanagawa H, Nakamura Y, Yashiro M, Oki I, Hirata S, Zhang T, et al. Incidence survey of Kawasaki disease in 1997 and 1998 in Japan. Pediatrics. 2001;107:E33.
4. Du ZD, Zhang T, Liang L, Meng X, Li T, Kawasaki T, et al. Epidemiologic picture of Kawasaki disease in Beijing from 1995 through 1999. Pediatr Infect Dis J. 2002;21:103-7.
5. Newburger JW, Taubert KA, Shulman ST, Rowley AH, Gewitz MH, Takahashi M, et al. Summary and abstracts of the Seventh International Kawasaki Disease Symposium: December 4-7, 2001, Hakone, Japan. Pediatr Res. 2003;53:153-7.
6. Chang LY, Chang IS, Lu CY, Chiang BL, Lee CY, Chen PJ, et al. Epidemiologic features of Kawasaki disease in Taiwan, 1996-2002. Pediatrics. 2004;114:e678-82.
7. Burns JC, Glodé MP. Kawasaki syndrome. Lancet. 2004;364:533-44.
8. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 2004;110:2747-71.
9. Hsu YH, Wang YH, Hsu WY, Lee YP. Kawasaki disease characterized by erythema and induration at the Bacillus Calmette-Guérin and purified protein derivative inoculation sites. Pediatr Infect Dis J. 1987;6:576-8.
10. Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med. 1991;324:1633-9.
11. Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, Duffy CE, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med. 1986;315:341-7.
12. Wang CL, Wu YT, Liu CA, Kuo HC, Yang KD. Kawasaki disease: infection, immunity and genetics. Pediatr Infect Dis J. 2005;24:998-1004.
13. Wang CL, Wu YT, Lee CJ, Liu HC, Huang LT, Yang KD. Decreased nitric oxide production after intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr. 2002;141:560-5.
14. Furukawa S, Matsubara T, Yabuta K. Mononuclear cell subsets and coronary artery lesions in Kawasaki disease. Arch Dis Child. 1992;67:706-8.
15. Furukawa S, Matsubara T, Jujoh K, Sasai K, Nakachi S, Sugawara T, et al. Reduction of peripheral blood macrophages/monocytes in Kawasaki disease by intravenous gammaglobulin. Eur J Pediatr. 1990;150:43-7.
16. Nathan DG, Orkin SH, Look AT, Ginsburg D, eds. Nathan and Oski's hematology of infancy and childhood. 6th ed. Philadelphia: WB Saunders; 2003:963.
17. Behrman RE, Kliegman RM, Jenson HB, eds. Nelson textbook of pediatrics. 17th ed. Philadelphia: WB Saunders; 2004:1605.
18. Morikawa Y, Ohashi Y, Harada K, Asai T, Okawa S, Nagashima M, et al. Coronary risks after high-dose gamma-globulin in children with Kawasaki disease. Pediatr Int. 2000;42:464-9.
19. Burns JC, Capparelli EV, Brown JA, Newburger JW, Glode MP. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group. Pediatr Infect Dis J. 1998;17:1144-8.
20. Mori M, Imagawa T, Yasui K, Kanaya A, Yokota S. Predictors of coronary artery lesions after intravenous gamma-globulin treatment in Kawasaki disease. J Pediatr. 2000;137:177-80.
21. Beiser AS, Takahashi M, Baker AL, Sundel RP, Newburger JW. A predictive instrument for coronary artery aneurysms in Kawasaki disease. US Multicenter Kawasaki Disease Study Group. Am J Cardiol. 1998;81:1116-20.